ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP cut its position in ICU Medical, Inc. (NASDAQ:ICUI) by 8.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,464 shares of the medical instruments supplier’s stock after selling 324 shares during the period. Bridgewater Associates LP’s holdings in ICU Medical were worth $631,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of ICUI. Innealta Capital LLC purchased a new stake in ICU Medical during the 2nd quarter worth about $32,000. Hexagon Capital Partners LLC lifted its stake in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP boosted its holdings in ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares in the last quarter. Venturi Wealth Management LLC increased its stake in ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in ICU Medical during the second quarter worth approximately $70,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Stock Down 1.8 %

ICU Medical stock opened at $160.96 on Tuesday. The stock has a 50 day moving average of $174.60 and a two-hundred day moving average of $147.67. ICU Medical, Inc. has a twelve month low of $83.26 and a twelve month high of $196.26. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of -35.22 and a beta of 0.66. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Jefferies Financial Group started coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 target price for the company. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. Raymond James lifted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, November 13th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $173.00.

Insider Transactions at ICU Medical

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. The trade was a 10.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Christian B. Voigtlander sold 1,962 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock worth $6,869,878 over the last 90 days. 6.70% of the stock is currently owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.